Study suggests PD-1 inhibitors against aggressive pediatric brain cancer subtype

January 29, 2018, CU Anschutz Medical Campus
Study suggests PD-1 inhibitors against aggressive pediatric brain cancer subtype
Andrea Griesinger, MS, and colleagues suggest supratentorial pediatric ependymoma may be susceptible to PD-1 inhibitors. Credit: University of Colorado Cancer Center

One type of immunotherapy removes a genetic blindfold that cancer uses to hide from the immune system. These "PD-1 inhibitors", including drugs like pembrolizumab, nivolumab and atezolizumab, have proven useful and have even in some cases revolutionized the treatment of common adult cancers ranging from melanoma, to lung cancer, to kidney cancer and more. Now PD-1 inhibitors are entering clinical trials to treat childhood cancers. A University of Colorado Cancer Center study published in the journal Pediatric Blood Cancers lays the scientific groundwork for the use of PD-1 inhibitors with an aggressive form of brain cancer, namely supratentorial pediatric ependymoma.

"This is a tumor with poor prognosis. Overall, pediatric cancers have a nearly 90 percent survival rate. But only 60 percent of patients with the most common form of supratentorial ependymoma will be alive five years after diagnosis," says study senior author, Andrea Griesinger, MS, senior professional research assistant in the lab of Nick Foreman, MD, CU Cancer Center investigator and Seebaum/Tschetter Chair of Pediatric Neuro-Oncology at Children's Hospital Colorado.

The tumor, which occurs in the upper part of the brain, namely the cerebral hemisphere, has two common genetic causes. The current study focuses on those tumors driven by changes to the gene RELA. When this gene improperly fuses with a partner gene, the resulting protein amplifies the action of a -causing cascade of signals through a network called NF- B, which is implicated in many cancer types.

"RELA-fusion hasn't been found in other cancer types. But NF- B amplification by other means is fairly common in cancer. RELA-fusion is another way to amplify NF- B, which causes this cancer," says Davis Witt, MS, professional research assistant in the Foreman lab and the paper's first author.

However, just as these supratentorial RELA-fusion pediatric ependymomas have genetic features that drive their growth, Witt, Griesinger and colleagues show that these tumors have a feature that may be a kind of Achille's heel that allows them to be killed. Specifically, the study shows that unlike other variations of pediatric ependymoma, the tumors driven by RELA-fusion coat themselves in the protein PD-L1. This PD-L1 on the surface of cancer interacts with the protein PD-1 on immune system T cells to inactivate T cells against cancer cells. It's as if PD-L1 is cancer's "white flag" that is seen by PD-1 "eyes" on immune system T cells. PD-1 inhibitors block the interaction between PD-L1 and PD-1, and thus nix cancer cells' ability to turn off the immune system.

The study required the unique resource of pediatric ependymoma cells lines, created for the first time in the Foreman lab.

"A major hurdle in ependymoma research has been a lack of cell lines and animal models. Over the last five years, we've been actively developing these cell lines that allow us to examine the biologic features of this disease. Just last week we were finally able to use these cells lines to develop an animal model of the disease, which will allow us to test likely treatments, in this case possibly anti-PD-1 drugs," says Griesinger.

In fact, a clinical trial of the anti-PD-1 drug nivolumab recently opened to treat . In early-phase clinical trials, investigators expect that some patients will benefit while others will not. The current study may hint at which pediatric brain cancer patients are most likely to see benefit from nivolumab or other anti-PD-L1 drugs, namely patients with these supratentorial RELA-fusion pediatric ependymomas that use PD-L1 so extensively.

"It's almost like we're backfilling the science behind this trial and providing information to use when designing future trials," Witt says. "If the trial doesn't work, we could go back and say 'hey, we just picked the wrong tumor,' and perhaps focus on this subtype of pediatric brain cancer that, according to the science, should be especially susceptible to PD-1 inhibitors."

Now that early cell studies have proved promising, Witt, Griesinger and other members of the Foreman lab plan to continue exploring the use of PD-1 inhibitors against supratentorial RELA-fusion pediatric ependymomas. This will include drug testing against and the development of "humanized" mouse models in which animals with this type of tumor are engineered to hold a version of the human immune system, allowing investigators to evaluate human-like immune responses against the cancer.

"This RELA-fusion subgroup is uniquely expressing high levels of PD-1. At this point, we're all very hopeful this means these tumors will be susceptible to anti-PD-1 drugs," Witt says.

Explore further: Cancer researchers hit a bullseye with new drug target for Ewing sarcoma

More information: Davis A. Witt et al, Specific expression of PD-L1 in RELA-fusion supratentorial ependymoma: Implications for PD-1-targeted therapy, Pediatric Blood & Cancer (2018). DOI: 10.1002/pbc.26960

Related Stories

Cancer researchers hit a bullseye with new drug target for Ewing sarcoma

January 25, 2018
Screening a class of recently-developed drug compounds—so-called "CDK inhibitors" capable of blocking CDK7/12/13 proteins—against hundreds of different human cancer cell lines, researchers at Dana-Farber/Boston Children's ...

Gene sequencing project discovers common driver of a childhood brain tumor

February 19, 2014
The St. Jude Children's Research Hospital-Washington University Pediatric Cancer Genome Project has identified the most common genetic alteration ever reported in the brain tumor ependymoma and evidence that the alteration ...

Molecular super enhancers: A new key for targeted therapy of brain cancer in children

December 20, 2017
Ependymoma refers to a heterogeneous group of cancers that can occur at any age, and is one of the most common types of brain cancer in children. The genetic causes for its development are largely unknown and there are no ...

Gene fusion shifts cell activity into high gear, causing some cancer

January 3, 2018
The fusion of two adjacent genes can cause cancer by kicking mitochondria into overdrive and increasing the amount of fuel available for rampant cell growth, researchers at Columbia University Medical Center (CUMC) have discovered. ...

Two-drug combination may boost immunotherapy responses in lung cancer patients

November 30, 2017
Johns Hopkins Kimmel Cancer Center researchers and colleagues have identified a novel drug combination therapy that could prime nonsmall cell lung cancers to respond better to immunotherapy. These so-called epigenetic therapy ...

Lung cancer driver ALK-fusion found in melanoma

October 23, 2017
Melanomas caused by sun exposure have been matched with targeted treatments and immunotherapies, in many cases dramatically extending patients' lives. However, there are other kinds of melanoma not related to sun exposure ...

Recommended for you

Fully reprogrammed virus offers new hope as cancer treatment

May 25, 2018
A cancer treatment that can completely destroy cancer cells without affecting healthy cells could soon be a possibility, thanks to research led by Cardiff University.

Research could help fine-tune cancer treatment

May 25, 2018
Cancer therapies that cut off blood supply to a tumour could be more effective in combination with existing chemotherapeutic drugs—according to new research from the University of East Anglia.

Increasing physical activity linked to better immunity in breast cancer patients, study finds

May 25, 2018
A new study from the University of Toronto's Faculty of Kinesiology & Physical Education has found that moderate to vigorous physical activity may help regulate the levels of C-reactive protein – an important biomarker ...

Low-fat diet tied to better breast cancer survival

May 24, 2018
(HealthDay)—Breast cancer patients who adopted a low-fat diet were more likely to survive for at least a decade after diagnosis, compared to patients who ate fattier fare, new research shows.

A cascade of immune processes offers insights to triple-negative breast cancer

May 24, 2018
Cancer is crafty. To survive and thrive, tumors find a way of thwarting our body's natural systems.

By forming clots in tumors, immune cell aids lung cancer's spread

May 24, 2018
University of North Carolina Lineberger Comprehensive Cancer Center researchers have found that by helping to form clots within tumors, immune cells that flock to a particular type of lung cancer are actually building a foundation ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.